ISRCTN90823663已完成未知
Efficacy and tolerability of artemether lumefantrine and amodiaquine artesunate for the treatment of uncomplicated falciparum malaria in Burkina Faso
ational Malaria Control Program (Burkina Faso)0 个研究点目标入组 780 人开始时间: 2012年1月30日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 780
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Age > 6 months
- •2. Weight > 5 kg
- •3. Fever (> 37.5ºC axillary) or history of fever in the previous 24 hours
- •4. Absence of any history of serious side effects to study medications
- •5. No evidence of a concomitant febrile illness
- •6. Provision of informed consent and agreement to follow-up for 28 days
- •7. No evidence of severe malaria or danger signs
- •8. Absence of repeated vomiting of study medications on day 0
- •9. P. falciparum mono-infection
- •10. Parasite density > 2000/ul and < 200,000/ul
排除标准
- •1. Severe malaria
- •2. Unable to respect the follow-up schedule
- •3. Known allergy to the study medication
- •4. Other chronic disease requiring care
研究者
相似试验
已完成
4 期
Efficacy and safety of Artemether - Lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in in sentinel sites in Mozambique.Infection - Studies of infection and infectious agentsMalariaACTRN12616001680459Ministry of Health352
已完成
不适用
Safety and efficacy of artemether-lumefantrine therapy for Intermittent Preventive Treatment in pregnancy in UgandaMalariaISRCTN12394097ICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR)1,664
招募中
4 期
Ethiopia P. vivax and P. falciparum in-vivo Effectiveness Study 2021-22MalariaPACTR202110520435408ICAP at Columbia University402
尚未招募
不适用
Efficacy and safety of artemether-lumefantrine, artesunate-amodiaquine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in three provinces in AngolaInfection - Studies of infection and infectious agentsMalariaACTRN12615000107527Ministry of Health600
已完成
不适用
Therapeutic efficacy testing of drugMalariaPACTR201709002064150ational Malaria Elimination Programme